Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
2024年10月29日 - 11:53PM
Edgar (US Regulatory)
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO
RULE 13A-16 OR 15D-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
October, 2024
Commission
File Number 1-15182
DR.
REDDY’S LABORATORIES LIMITED
(Translation of registrant’s name into English)
8-2-337, Road No. 3, Banjara Hills
Hyderabad, Telangana 500 034, India
+91-40-49002900
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F x Form 40-F ¨
Indicate by check mark if the registrant is submitting the Form 6-K
in paper as permitted by Regulation S-T Rule 101(b)(1): ______
Note: Regulation S-T Rule 101(b)(1) only permits the submission
in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.
Indicate by check mark if the registrant is submitting the Form 6-K
in paper as permitted by Regulation S-T Rule 101(b)(7): ______
Note: Regulation S-T Rule 101(b)(7) only
permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer
must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized
(the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities
are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the
registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other
Commission filing on EDGAR.
Indicate by check mark whether by furnishing the
information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b)
under the Securities Exchange Act of 1934.
Yes
¨ No x
If “Yes” is marked, indicate below the file number assigned
to registrant in connection with Rule 12g3-2(b): 82-________.
EXHIBITS
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
DR. REDDY’S LABORATORIES LIMITED
(Registrant) |
|
|
|
Date: October 29, 2024 |
By: |
/s/ K Randhir Singh |
|
|
Name: |
K Randhir Singh |
|
|
Title: |
Company Secretary |
Exhibit 99.1
|
Dr. Reddy’s Laboratories Ltd.
8-2-337, Road No. 3, Banjara Hills,
Hyderabad - 500 034, Telangana,
India.
CIN : L85195TG1984PLC004507
Tel : +91 40 4900 2900
Fax : +91 40 4900 2999
Email : mail@drreddys.com
www.drreddys.com |
October 29, 2024
National Stock Exchange of India Ltd. (Stock Code:
DRREDDY-EQ)
BSE Limited (Stock Code: 500124)
New York Stock Exchange Inc. (Stock Code: RDY)
NSE IFSC Ltd. (Stock Code: DRREDDY)
Dear Sir/Madam,
Sub: Update on Stock Split
In furtherance to our intimation dated October
04, 2024 regarding intimation of record date as October 28, 2024 for sub-division/ split of each equity share of Rs. 5/- (Rupees five
only) each, fully paid-up into 5 (five) equity shares of Re. 1/- (Rupee one only) each, fully paid-up, kindly note the Company’s
authorized, issued and paid-up share capital as on October 28, 2024, pre and post sub-division as set out below:
Particulars |
Pre sub-division |
Post sub-division |
Authorised Share Capital |
Rs. 1,45,00,00,000/- divided into 29,00,00,000 equity shares of Rs. 5/- each |
Rs. 1,45,00,00,000/- divided into 1,45,00,00,000 equity shares of Re. 1/- each |
Issued Share Capital |
Rs. 83,43,85,730/- divided into 16,68,77,146 equity shares of Rs. 5/- each |
Rs. 83,43,85,730/- divided into 83,43,85,730 equity shares of Re. 1/- each |
Paid-up Share Capital |
Rs. 83,43,84,730/- divided into 16,68,76,946 equity shares of Rs. 5/- each |
Rs. 83,43,84,730/- divided into 83,43,84,730 equity shares of Re. 1/- each |
Note: The difference between issued and paid-up
capital is due to forfeiture of 200 shares of Rs.5/- each, pre sub-division, resulting in 1000 shares of Re.1/- each, post sub-division.
This is for your information and records.
Thanking you.
Yours faithfully,
For Dr. Reddy’s Laboratories Limited
K Randhir Singh
Company Secretary, Compliance Officer &
Head-CSR
Dr Reddys Laboratories (NYSE:RDY)
過去 株価チャート
から 10 2024 まで 11 2024
Dr Reddys Laboratories (NYSE:RDY)
過去 株価チャート
から 11 2023 まで 11 2024